Holen Sie sich die Stockscreener-App
38.34
6.10%
-2.49
Handel nachbörslich:
38.45
0.11
+0.29%
Schlusskurs vom Vortag:
$40.83
Offen:
$40.85
24-Stunden-Volumen:
1.37M
Relative Volume:
0.78
Marktkapitalisierung:
$4.03B
Einnahmen:
$741.17M
Nettoeinkommen (Verlust:
$104.65M
KGV:
43.81
EPS:
0.8752
Netto-Cashflow:
$162.57M
1W Leistung:
-0.05%
1M Leistung:
+2.62%
6M Leistung:
-47.90%
1J Leistung:
-45.35%
1-Tages-Spanne:
$38.00
$40.85
1-Wochen-Bereich:
$38.00
$41.92
52-Wochen-Spanne:
$32.99
$117.33
Corcept Therapeutics Inc Stock (CORT) Company Profile
Firmenname
Corcept Therapeutics Inc
Sektor
Branche
Telefon
650.688.8803
Adresse
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
38.34 | 4.29B | 741.17M | 104.65M | 162.57M | 0.8752 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-31 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2025-12-16 | Eingeleitet | UBS | Neutral |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-11-06 | Hochstufung | Truist | Hold → Buy |
| 2023-04-11 | Eingeleitet | SVB Securities | Market Perform |
| 2023-04-04 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-15 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-01 | Herabstufung | Truist | Buy → Hold |
| 2022-07-27 | Hochstufung | Jefferies | Hold → Buy |
| 2022-06-27 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-01-28 | Eingeleitet | Truist | Buy |
| 2020-08-05 | Herabstufung | Jefferies | Buy → Hold |
| 2019-09-24 | Eingeleitet | Jefferies | Buy |
| 2019-09-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-02-04 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | Bestätigt | Stifel | Hold |
| 2018-05-31 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-09 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | Eingeleitet | Stifel | Buy |
| 2017-02-02 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2015-04-21 | Eingeleitet | FBR Capital | Outperform |
| 2014-01-13 | Herabstufung | Stifel | Buy → Hold |
| 2013-08-09 | Herabstufung | Janney | Buy → Neutral |
| 2013-08-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | Bestätigt | JMP Securities | Mkt Outperform |
| 2010-01-06 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | Hochstufung | Punk, Ziegel & Co | Mkt Perform → Accumulate |
Alle ansehen
Corcept Therapeutics Inc Aktie (CORT) Neueste Nachrichten
CORCEPT THERAPEUTICS INCORPORATED (NASDAQ: CORT) - GlobeNewswire
Options Exercise: Hazel Hunt At Corcept Therapeutics Realizes $5.53M - Benzinga
CORCEPT THERAPEUTICS Investors Are Encouraged to Contact Kaplan Fox & Kilsheimer LLP Regarding Potential Securities Law Violations - NewMediaWire
CORCEPT THERAPEUTICS INVESTIGATION ALERT: Corcept Therapeutics Faces Potential Securities Law ViolationsContact Kaplan Fox & Kilsheimer LLP - NewMediaWire
Corcept Therapeutics Faces Potential Securities Law ViolationsContact Kaplan Fox & Kilsheimer LLP - FinancialContent
CORCEPT THERAPEUTICS INCORPORATED (NASDAQ: CORT) INVESTIGATION ALERT: Bernstein Liebhard is ... - Bluefield Daily Telegraph
CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm - GlobeNewswire Inc.
CORT INVESTIGATION ALERT: Investigation Launched into Corcept Therapeutics (CORT), Hagens Berman Encourages Investors to Contact Firm - PR Newswire
CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm - PR Newswire
CORT shares plummet on FDA’s drug rejection letter reveal — here’s what retail has to say - MSN
CORT SECURITIES INVESTIGATION: Kaplan Fox is Investigating Possible Securities Violations Against Corcept Therapeutics, Inc. (CORT) - The Globe and Mail
Kaplan Fox is Investigating Possible Securities Violations Against Corcept Therapeutics, Inc. (CORT) - FinancialContent
CORCEPT THERAPEUTICS Is Being Investigated for Potential Securities Law ViolationsContact Kaplan Fox & Kilsheimer LLP - NewMediaWire
FinancialContentCORCEPT THERAPEUTICS Is Being Investigated for Potential Securities Law ViolationsContact Kaplan Fox & Kilsheimer LLP - FinancialContent
Insider Sell: William Guyer Sells 20,000 Shares of Corcept Thera - GuruFocus
Insider Sell: William Guyer Sells 20,000 Shares of Corcept Therapeutics Inc (CORT) - GuruFocus
CORCEPT THERAPEUTICS SECURITIES INVESTIGATION: Kaplan Fox & Kilsheimer LLP is Investigating Corcept Therapeutics, Inc. (CORT) for Possible Securities Law Violations - The Globe and Mail
Despite lower earnings than three years ago, Corcept Therapeutics (NASDAQ:CORT) investors are up 71% since then - Yahoo Finance
CORT Investors Have Opportunity to Join Corcept Therapeutics Inc - GuruFocus
Corcept Therapeutics Incorporated (NASDAQ:CORT) Given Average Rating of "Hold" by Brokerages - MarketBeat
CORCEPT INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
Lost Money on Corcept Therapeutics Incorporated (CORT)? Possible FraudContact Levi & Korsinsky Today - marketscreener.com
Securities Fraud Investigation Into Corcept Therapeutics Incorporated (CORT) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - The AI Journal
Published on: 2026-02-04 10:56:05 - baoquankhu1.vn
Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - marketscreener.com
Securities Fraud Investigation Into Corcept Therapeutics Incorporated (CORT) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - The AI Journal
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Corcept ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Corcept Therapeutics Incorporated – CORT - ChartMill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nutanix, Inc. - GlobeNewswire Inc.
Brown Capital Management LLC Makes New $19.95 Million Investment in Corcept Therapeutics Incorporated $CORT - MarketBeat
CORT FRAUD INVESTIGATION: Kaplan Fox Alerts Investors of Corcept Therapeutics, Inc. (CORT) to Potential Securities Violations - NewMediaWire
FDA Warned Corcept of ‘Significant Review Issues’ for Rejected Drug in Early Meetings - BioSpace
DJS Law Group Investigates Corcept Securities Violations - intellectia.ai
Rosen Law Firm Investigates Securities Claims for Corcept Shareholders - intellectia.ai
Hagens Berman Investigating Corcept Therapeutics (CORT): Shares F - The National Law Review
Kaplan Fox Alerts Investors of Corcept Therapeutics, Inc. (CORT) to an Investigation of Possible Securities Law Violations - NewMediaWire
Corcept Therapeutics Faces FDA Warning Over Drug Efficacy Claims - intellectia.ai
Hagens Berman Investigating Corcept Therapeutics (CORT): Shares Fall After Report That FDA Warned Against Relacorilant Drug Application Filing - The AI Journal
Corcept Therapeutics (CORT) Shares Drop After FDA Feedback - GuruFocus
Berman Tabacco Announces Investigation of Corcept - GlobeNewswire
Corcept submitted lead asset for approval despite FDA flagging risk of 'significant review issues' - Fierce Biotech
CORT Shares Plummet On FDA’s Drug Rejection Letter Reveal — Here’s What Retail Has To Say - Stocktwits
CORT Sees Increased Call Options Activity - GuruFocus
Rosen Law Firm Encourages Corcept Therapeutics Incorporated Investors to Inquire About Securities Class Action Investigation – CORT - Business Wire
Commit To Purchase Corcept Therapeutics At $25, Earn 18.7% Annualized Using Options - Nasdaq
Corcept shares tumble after FDA letter reveals warnings before drug rejection - Yahoo! Finance Canada
Corcept Therapeutics Investigated for Securities Fraud Following Report of FDA Warnings; Shareholders Should Contact Block & Leviton To Recover Losses - GlobeNewswire
Corcept Therapeutics (CORT) Stock Falls After FDA Rejects Drug A - GuruFocus
Corcept stock down as FDA revises CRL (CORT:NASDAQ) - Seeking Alpha
Finanzdaten der Corcept Therapeutics Inc-Aktie (CORT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Corcept Therapeutics Inc-Aktie (CORT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Guyer William | Chief Development Officer |
Feb 03 '26 |
Option Exercise |
21.65 |
20,000 |
433,000 |
21,235 |
| Guyer William | Chief Development Officer |
Feb 03 '26 |
Sale |
40.87 |
20,000 |
817,334 |
1,235 |
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):